Gaithersburg, MD, United States of America

Robert W Georgantas, Iii

USPTO Granted Patents = 3 

Average Co-Inventor Count = 9.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
3 patents (USPTO):

Title: The Innovations of Robert W Georgantas, III

Introduction

Robert W Georgantas, III is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biomedical research, particularly in the area of biomarkers for IL23-mediated diseases. With a total of three patents to his name, his work has the potential to impact the treatment of conditions such as Crohn's disease.

Latest Patents

Georgantas' latest patents include innovative methods for using CCL20 as a predictor of clinical response to IL23-antagonists. This invention focuses on utilizing the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to identify patients who may respond to anti-IL23 treatments. The patent outlines how levels of CCL20 can help determine patient eligibility for treatment, guide treatment decisions, and predict treatment outcomes. Another significant patent involves the prediction of clinical response to IL23-antagonists using components of the IL23 pathway as biomarkers, such as IL22 and lipocalin-2 (LCN2). This invention also aims to stratify patients suffering from IL23-mediated diseases, enhancing the precision of therapeutic interventions.

Career Highlights

Throughout his career, Robert W Georgantas, III has worked with prominent companies in the biotechnology sector, including MedImmune Limited and Amgen Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions for complex medical challenges.

Collaborations

Georgantas has collaborated with notable colleagues such as Koustubh Ranade and Katie Streicher. These partnerships have likely fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Robert W Georgantas, III is a distinguished inventor whose work in biomarker research has the potential to transform the treatment landscape for IL23-mediated diseases. His contributions through patents and collaborations highlight the importance of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…